계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
EGenesis
company
About
EGenesis focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs.
- 1 - 10
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $100M
- Industries
- Biopharma,Biotechnology,Genetics,Life Science,Medical
- Founded date
- Jan 1, 2014
- Number Of Employee
- 1 - 10
- Operating Status
- Active
EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$263M
EGenesis has raised a total of
$263M
in funding over 2 rounds. Their latest funding was raised on
Mar 2, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 2, 2021 | Series C | $125M | 1 | — | — | Detail |
| Nov 7, 2019 | Series B | $100M | 2 | — | — | Detail |
| Mar 16, 2017 | Series A | $38M | 2 |
ARCH Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
EGenesis is funded by 3 investors.
ARCH Venture Partners
and Bayer
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
— | Series C |
Bayer
|
— | Series B |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
